个人简历

1987.9-1991.7，武汉大学生物系，微生物学专业，获学士学位；

1991.9-1996.12，中国科学院上海植物生理研究所，微生物学专业，获博士学位；

1997.1-1999.12，Public Health Research Institute, New York, USA；博士后；

2000.1-2004.8，Public Health Research Institute, New York, USA；研究助理；

2004.9-至今，bat365官网登录入口微生物研究所；研究员

主要研究方向

主要从事细菌抗药机制及微生物活性天然产物生物合成研究。

1．细菌抗药机制：为了应对日益严重的细菌抗药性问题，对细菌应激反应和抗药机制进行了研究。发现了一些功能未知的新基因参与了细菌的应激反应并在逆境下对细菌具有保护作用，揭示了其中部分关键基因的作用机制及其与细菌对药物敏感性的关系。对细菌抗药机制的研究一方面可以使我们进一步了解细菌与外界环境的相互作用，另一方面也为我们促进现有药物药效、减缓细菌抗药性的产生提供新的思路。

2.微生物活性天然产物生物合成：开展了放线菌次生代谢产物功能基因组的研究，对具有自主知识产权的新型抗肿瘤化合物自溶霉素和新型农药新磷氮霉素A的生物合成途径中关键基因的功能进行了研究，并对其生物合成进行了基因工程改良，为进一步研发奠定了基础。

主要论文

1. Dorsey-Oresto, A., Lu, T., Mosel, M., Wang, X., Salz, T., Drlica, K. & Zhao, X. YihE Kinase Is a Central Regulator of Programmed Cell Death in Bacteria. Cell Reports 3, 528-537 (2013). Co-first author

2. Han, X., Li, M., Ding, Z., Zhao, J., Ji, K., Wen, M. & Lu, T. Genome Sequence of Streptomyces auratus Strain AGR0001, a Phoslactomycin-Producing Actinomycete. Journal of Bacteriology 194, 5472-5473 (2012).

3. Yin, M., Lu, T., Zhao, L.X., Chen, Y., Huang, S.X., Lohman, J.R., Xu, L.H., Jiang, C.L. & Shen, B. The missing C-17 O-methyltransferase in geldanamycin biosynthesis. Organic Letters 13, 3726-3729 (2011).

4. Han, X., Geng, J., Zhang, L. & Lu, T. The role of Escherichia coli YrbB in the lethal action of quinolones. The Journal of Antimicrobial Chemotherapy 66, 323-331 (2011).

5. Han, X., Dorsey-Oresto, A., Malik, M., Wang, J.Y., Drlica, K., Zhao, X. & Lu, T. Escherichia coli genes that reduce the lethal effects of stress. BMC Microbiology 10, 35 (2010).

6. Malik, M., Lu, T., Zhao, X., Singh, A., Hattan, C.M., Domagala, J., Kerns, R. & Drlica, K. Lethality of quinolones against Mycobacterium smegmatis in the presence or absence of chloramphenicol. Antimicrobial Agents and Chemotherapy 49, 2008-2014 (2005).

7. Lu, T., Zhao, X., Li, X., Hansen, G., Blondeau, J. & Drlica, K. Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. The Journal of Antimicrobial Chemotherapy 52, 61-64 (2003).

8. Lu, T. & Drlica, K. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents. The Journal of Antimicrobial Chemotherapy 52, 1025-1028 (2003).

9. Lu, T., Zhao, X., Li, X., Drlica-Wagner, A., Wang, J.Y., Domagala, J. & Drlica, K. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 45, 2703-2709 (2001).

10. Lu, T., Zhao, X. & Drlica, K. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrobial Agents and Chemotherapy 43, 2969-2974 (1999).